PMID- 35710477
OWN - NLM
STAT- MEDLINE
DCOM- 20220907
LR  - 20220907
IS  - 1769-6917 (Electronic)
IS  - 0007-4551 (Linking)
VI  - 109
IP  - 9
DP  - 2022 Sep
TI  - Blockade of TIM-3 and PD-1 enhances the antitumor effects of MAGE-A11 
      antigen-specific cytotoxic T lymphocytes.
PG  - 895-908
LID - S0007-4551(22)00162-X [pii]
LID - 10.1016/j.bulcan.2022.04.005 [doi]
AB  - Cancer immunotherapy is an attractive approach for antigen-specific T 
      cell-mediated antitumor therapy, especially for the induction of cytotoxic T 
      lymphocytes (CTLs). An human leukocyte antigen (HLA)-A2-restricted 
      melanoma-associated antigen-A11 (MAGE-A11) peptide was developed that exhibited a 
      potent capacity to induce cytotoxicity towards MAGE-A11-positive breast cancer 
      cells by activating CTLs. However, this antitumor immune response can be 
      suppressed by inhibitory pathways. Programmed death-1 (PD-1) and T cell 
      immunoglobulin domain and mucin domain 3 (TIM-3) pathways are two important 
      pathways involved in the tumor-mediated immune suppression. The present study 
      aimed to augment the efficacy of MAGE-A11 antigen-specific CTLs via blocking PD-1 
      and TIM-3. The results showed that the expression levels of PD-1 and TIM-3 were 
      unregulated during T cell induction, expansion and target cell killing. Blockade 
      of PD-1 and TIM-3 modulated T cell proliferation, transformation and survival. In 
      addition, treatment of cells with antibodies against PD-1 and TIM-3 enhanced the 
      cytotoxicity of MAGE-A11 antigen-specific CTLs against breast cancer cells. The 
      aforementioned findings suggested that MAGE-A11 antigen-specific CTLs accompanied 
      by PD-1 and TIM-3 blockade could be considered as a potential therapy approach 
      for breast cancer.
CI  - Crown Copyright (c) 2022. Published by Elsevier Masson SAS. All rights reserved.
FAU - Zhang, Jiandong
AU  - Zhang J
AD  - Clinical Laboratory, The Third Hospital of Hebei Medical University, Shijiazhuang 
      050011, PR China.
FAU - Zhang, Fengxia
AU  - Zhang F
AD  - Nursing department, Hengshui Health School, Hengshui 050000, PR China.
FAU - Wu, Hua
AU  - Wu H
AD  - Clinical Laboratory, The Third Hospital of Hebei Medical University, Shijiazhuang 
      050011, PR China.
FAU - Zhang, Bei
AU  - Zhang B
AD  - Clinical Laboratory, The Third Hospital of Hebei Medical University, Shijiazhuang 
      050011, PR China.
FAU - Zhang, Xiaoming
AU  - Zhang X
AD  - Clinical Laboratory, The Third Hospital of Hebei Medical University, Shijiazhuang 
      050011, PR China.
FAU - Wu, Xiangyun
AU  - Wu X
AD  - Clinical Laboratory, The Third Hospital of Hebei Medical University, Shijiazhuang 
      050011, PR China. Electronic address: wuxiangyunjyk@126.com.
LA  - eng
PT  - Journal Article
DEP - 20220614
PL  - France
TA  - Bull Cancer
JT  - Bulletin du cancer
JID - 0072416
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Hepatitis A Virus Cellular Receptor 2)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - *Breast Neoplasms/drug therapy
MH  - Female
MH  - HLA-A2 Antigen
MH  - Hepatitis A Virus Cellular Receptor 2
MH  - Humans
MH  - Programmed Cell Death 1 Receptor
MH  - *T-Lymphocytes, Cytotoxic
OTO - NOTNLM
OT  - Blockade
OT  - Cytotoxic T lymphocyte
OT  - PD-1
OT  - TIM-3
EDAT- 2022/06/17 06:00
MHDA- 2022/09/08 06:00
CRDT- 2022/06/16 23:45
PHST- 2021/10/14 00:00 [received]
PHST- 2022/03/16 00:00 [revised]
PHST- 2022/04/11 00:00 [accepted]
PHST- 2022/06/17 06:00 [pubmed]
PHST- 2022/09/08 06:00 [medline]
PHST- 2022/06/16 23:45 [entrez]
AID - S0007-4551(22)00162-X [pii]
AID - 10.1016/j.bulcan.2022.04.005 [doi]
PST - ppublish
SO  - Bull Cancer. 2022 Sep;109(9):895-908. doi: 10.1016/j.bulcan.2022.04.005. Epub 
      2022 Jun 14.